|
|
|
| home > pmps > spring 2019 > easing late-stage customisation in pharmaceutical logistics |
|
|
 PUBLICATIONS |
Pharmaceutical Manufacturing and Packing Sourcer
|
|
Late-stage customisation in pharmaceutical manufacturing includes, for example, adding variable data to labels or packaging that are pre-printed. This allows the manufacturer to customise product labelling for certain markets, customers, or products without having to stock individual packaging materials for each possible variant. Additionally, the flexible production of smaller batch sizes creates new requirements for automatic and fast changeovers. How can pharma manufacturers implement a tamper-evident, flexible solution for low and medium volume production?
Choosing Late- Stage Customisation
Government organisations around the world have initiated or already implemented laws and regulations that aim to ensure patient and consumer safety by preventing falsified and counterfeit medicines from illegally entering the supply chain. The EMA defines falsified medicines as those which may come in fake packaging or contain the wrong ingredients or low levels of the active ingredients (1). Counterfeit medicines are those that infringe trademark law or do not comply with intellectual property rights. Falsified and counterfeit medicines can pose serious risks to patients and consumers. For example, in the EU, pharmaceuticals need to be labelled and packaged specifically for each member state in which they are marketed, according to each country’s individual requirements. Counterfeiting can be reduced significantly by implementing product serialisation, which requires a system to track and trace medicines throughout the entire supply chain. Serialisation of prescription medicines will become mandatory in the EU on 9 February 2019. Similar regulations are already in place in other regions.
|
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
News and Press Releases |
 |
Sartorius Stedim Biotech Launches New Services for Mammalian Cell Bank Manufacturing
GOETTINGEN, Germany and GLASGOW, UK, August 08, 2019 / B3C newswire / -- Sartorius Stedim Biotech (SSB), a leading partner of the biopharmaceutical industry, today announced the launch of new services for mammalian cell bank manufacture under GMP conditions. These services are offered by its subsidiary, Sartorius Stedim BioOutsource, an experienced contract testing organization (CTO) based in Glasgow, UK, and in Cambridge, Massachusetts, USA.
More info >> |
|
 |
White Papers |
 |
|
The current and future role of the medical oncologist in the professional care for cancer patients: a position paper by the European Society for Medical Oncology
European Society for Medical Oncology (ESMO)
The number of cancer patients in Europe is rising and significant advances in basic and applied cancer research are making the provision of optimal care more challenging. The concept of cancer as a systemic, highly heterogeneous and complex disease has increased the awareness that quality cancer care should be provided by a multidisciplinary team (MDT) of highly qualified healthcare professionals. Cancer patients also have the right to benefit from medical progress by receiving optimal treatment from adequately trained and highly skilled medical professionals. Built on the highest standards of professional training and continuing medical education, medical oncology is recognised as an independent medical specialty in many European countries.
More info >> |
|
 |
Industry Events |
 |
2020 Avoca Quality and Innovation Summit
3-4 June 2020, Amsterdam, The Netherlands
The 2020 Avoca Quality and Innovation Summit will take place 3-4 June
2020, in Amsterdam, The Netherlands.
More info >> |
|
|
